<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02807922</url>
  </required_header>
  <id_info>
    <org_study_id>SleepRCT_270215</org_study_id>
    <secondary_id>2015-005306-11</secondary_id>
    <nct_id>NCT02807922</nct_id>
  </id_info>
  <brief_title>Pharmacological Treatment of Insomnia in Palliative Care</brief_title>
  <official_title>Pharmacological Treatment of Insomnia in Palliative Care: A Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial Investigating the Short Time Effect of Zopiclone on Self-reported Sleep Quality in Patients With Advanced Cancer Who Use Opioids and Who Report Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sleep disturbance is frequent in patients with advanced cancer and decreases the tolerability&#xD;
      of other symptoms and impairs quality of life. A detailed description of sleep disturbance&#xD;
      and its association with other symptoms, and intervention studies on sleep medications are&#xD;
      scarce in patients with advanced cancer. A well-designed randomized controlled trial is&#xD;
      needed to determine the short time effectiveness of zopiclone on sleep quality, one of the&#xD;
      currently available therapies of insomnia, and further to contribute to the clinical&#xD;
      management of insomnia in patients with advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical trial is a randomized, double-blind, placebo controlled, parallel-group,&#xD;
      multicenter trial investigating the short time effectiveness of zopiclone on self-reported&#xD;
      sleep quality in patients with advanced cancer who use opioids and who report insomnia.&#xD;
      Patients with advanced cancer who use opioids and who report insomnia are randomized to&#xD;
      either a hypnotic, zopiclone (Arm A) or placebo (Arm B) for six nights. For this study&#xD;
      zopiclone Actavis 3.75 mg, 5 mg and 7.5 mg (active comparator) and placebo are defined as&#xD;
      Investigational Medicinal Products. The initial dose is zopiclone/placebo 3.75 mg/day.&#xD;
      Evaluation of sleep quality is performed in the morning after night 2 and 4 with evaluation&#xD;
      of sleep quality by using a numerical rating scale 0-10 with the question &quot;Please circle the&#xD;
      number that best describes how you feel now&quot; 0= Best sleep, 10= Worst possible sleep.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Actual">July 13, 2021</completion_date>
  <primary_completion_date type="Actual">July 13, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient-reported sleep quality</measure>
    <time_frame>Night six (last study night)</time_frame>
    <description>Primary endpoint is patient-reported sleep quality during the final study night (night six) assessed on a numerical rating scale (NRS) 0-10. 0= Best sleep, 10=Worst possible sleep.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient reported total sleep time</measure>
    <time_frame>Night six (last study night)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported sleep onset latency</measure>
    <time_frame>Night six (last study night)</time_frame>
    <description>Sleep onset latency (how long (minutes) it takes to fall asleep</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Sleep</condition>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Zopiclone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zopiclone six nights</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo six nights</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zopiclone</intervention_name>
    <arm_group_label>Zopiclone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically verified malignant disease&#xD;
&#xD;
          2. Presence of metastatic / disseminated disease&#xD;
&#xD;
          3. Presence of insomnia syndrome defined as:&#xD;
&#xD;
               1. Self-reported difficulty with initiating sleep (greater than 30 minutes to sleep&#xD;
                  onset) and/or difficulty maintaining sleep (greater than 30 minutes nocturnal&#xD;
                  waking time); and&#xD;
&#xD;
               2. Sleep difficulty at least 3 nights per week; and&#xD;
&#xD;
               3. Sleep difficulty that causes significant impairment of daytime functioning (The&#xD;
                  patient will be asked if sleep difficulty result in altered daytime function i.e.&#xD;
                  feeling tired, lack of energy)&#xD;
&#xD;
          4. Able to comply with all study procedures&#xD;
&#xD;
          5. Signed informed consent and expected cooperation of the patients for the treatment and&#xD;
             follow up must be obtained and documented according to ICH GCP, and national/local&#xD;
             regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. On-going treatment or previous treatment (within last 4 weeks) for more than&#xD;
             consecutive 3 days with medications given for insomnia&#xD;
&#xD;
          2. Adverse reactions to zopiclone&#xD;
&#xD;
          3. History of substance abuse&#xD;
&#xD;
          4. Concomitant use of rifampicin and erythromycin&#xD;
&#xD;
          5. Any other contraindication listed on the summary of product characteristics of the&#xD;
             investigated medicinal product:&#xD;
&#xD;
               1. Myasthenia gravis&#xD;
&#xD;
               2. An established diagnosis of Severe impairment of respiratory function&#xD;
&#xD;
               3. An established diagnosis of Severe hepatic insufficiency.(Child-Pugh grade B or&#xD;
                  C)&#xD;
&#xD;
               4. An established diagnosis of sleep apnea&#xD;
&#xD;
               5. Known hypersensitivity to the drug or to any component in its formulation:&#xD;
                  Lactose monohydrate, Calcium hydrogen phosphate, Maize starch, Croscarmellose&#xD;
                  sodium, Magnesium stearate, Titanium dioxide (E 171), Hypromellose, Iron oxide&#xD;
                  yellow/Iron oxide red (E 172) and Macrogol&#xD;
&#xD;
          6. Unfit for participation for any reason as judged by the investigator&#xD;
&#xD;
          7. Pregnancy or lactation&#xD;
&#xD;
          8. Women of reproductive age not willing or unable to employ an effective method of&#xD;
             contraception (sterilization, using IUD or oral contraception)&#xD;
&#xD;
          9. Scheduled surgery within the next week&#xD;
&#xD;
         10. In the need of change in scheduled opioid dose at baseline (study visit 1)&#xD;
&#xD;
         11. Scheduled intravenous administration of chemotherapy during the study period (from&#xD;
             baseline to day 8) or intravenous administration of chemotherapy during the last week&#xD;
&#xD;
         12. Change in corticosteroid dose last week before baseline or planned dose change in&#xD;
             corticosteroid dose within 7 days from baseline&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pål Klepstad</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sunniva senter for lindrende behandling, Haraldsplass Diakonale sykehus</name>
      <address>
        <city>Bergen</city>
        <zip>5892</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>sykehuset Levanger</name>
      <address>
        <city>Levanger</city>
        <zip>7601</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helse Sør-Øst RHF, Sykehuset i Telemark,</name>
      <address>
        <city>Skien</city>
        <zip>3710</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helse Sør-Øst RHF, Sykehuset i Vestfold,</name>
      <address>
        <city>Tønsberg</city>
        <zip>3103</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Jakobsen G, Engstrøm M, Paulsen Ø, Sjue K, Raj SX, Thronæs M, Hjermstad MJ, Kaasa S, Fayers P, Klepstad P. Zopiclone versus placebo for short-term treatment of insomnia in patients with advanced cancer: study protocol for a double-blind, randomized, placebo-controlled, clinical multicenter trial. Trials. 2018 Dec 27;19(1):707. doi: 10.1186/s13063-018-3088-3.</citation>
    <PMID>30591073</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Palliative Care</keyword>
  <keyword>zopiclone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zopiclone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

